BT02
Phase 2Small molecule
BT02 is one of 85 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
199 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tagrisso
AstraZenecaPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Alunbrig
TakedaPhase 3
Alecensa
RochePhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
DATROWAY
Daiichi SankyoPhase 3
Lynparza
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed or Refractory Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BT02. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBiotroy Therapeutics